Your browser doesn't support javascript.
loading
Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid.
Kumar, Abhinav; Bicer, Elif Melis; Morgan, Anna Babin; Pfeffer, Paul E; Monopoli, Marco; Dawson, Kenneth A; Eriksson, Jonny; Edwards, Katarina; Lynham, Steven; Arno, Matthew; Behndig, Annelie F; Blomberg, Anders; Somers, Graham; Hassall, Dave; Dailey, Lea Ann; Forbes, Ben; Mudway, Ian S.
Affiliation
  • Kumar A; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK. Electronic address: abhinav.kumar@kcl.ac.uk.
  • Bicer EM; MRC-PHE Centre for Environment and Health and NIHR-HPRU in the Health Impact of Environmental Hazards, Environmental and Analytical Research, Division, Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Morgan AB; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK.
  • Pfeffer PE; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Monopoli M; Centre for BioNano Interactions, University College Dublin, Belfield, Dublin 4, Ireland.
  • Dawson KA; Centre for BioNano Interactions, University College Dublin, Belfield, Dublin 4, Ireland.
  • Eriksson J; Department of Chemistry - BMC, Uppsala University, Sweden.
  • Edwards K; Department of Chemistry - BMC, Uppsala University, Sweden.
  • Lynham S; Institute of Psychiatry, Psychology and Neuroscience, Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Arno M; Genomics Centre, Faculty of Life Sciences and Medicine, King's College, London, UK.
  • Behndig AF; Department of Public Health and Clinical Medicine, Division of Medicine/Respiratory Medicine and Allergy, Umeå University, Umeå, Sweden.
  • Blomberg A; Department of Public Health and Clinical Medicine, Division of Medicine/Respiratory Medicine and Allergy, Umeå University, Umeå, Sweden.
  • Somers G; GSK Medicines Research Centre, Stevenage, Hertfordshire, UK.
  • Hassall D; GSK Medicines Research Centre, Stevenage, Hertfordshire, UK.
  • Dailey LA; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK.
  • Forbes B; Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, LondonUK.
  • Mudway IS; MRC-PHE Centre for Environment and Health and NIHR-HPRU in the Health Impact of Environmental Hazards, Environmental and Analytical Research, Division, Faculty of Life Sciences and Medicine, King's College, London, UK.
Nanomedicine ; 12(4): 1033-1043, 2016 May.
Article in En | MEDLINE | ID: mdl-26767511
ABSTRACT
When inhaled nanoparticles deposit in the lungs, they transit through respiratory tract lining fluid (RTLF) acquiring a biomolecular corona reflecting the interaction of the RTLF with the nanomaterial surface. Label-free snapshot proteomics was used to generate semi-quantitative profiles of corona proteins formed around silica (SiO2) and poly(vinyl) acetate (PVAc) nanoparticles in RTLF, the latter employed as an archetype drug delivery vehicle. The evolved PVAc corona was significantly enriched compared to that observed on SiO2 nanoparticles (698 vs. 429 proteins identified); however both coronas contained a substantial contribution from innate immunity proteins, including surfactant protein A, napsin A and complement (C1q and C3) proteins. Functional protein classification supports the hypothesis that corona formation in RTLF constitutes opsonisation, preparing particles for phagocytosis and clearance from the lungs. These data highlight how an understanding of the evolved corona is necessary for the design of inhaled nanomedicines with acceptable safety and tailored clearance profiles. FROM THE CLINICAL EDITOR Inhaled nanoparticles often acquire a layer of protein corona while they go through the respiratory tract. Here, the authors investigated the identity of these proteins. The proper identification would improve the understanding of the use of inhaled nanoparticles in future therapeutics.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Respiratory System / Drug Delivery Systems / Nanoparticles / Protein Corona Limits: Adult / Female / Humans / Male Language: En Year: 2016 Type: Article

Full text: 1 Database: MEDLINE Main subject: Respiratory System / Drug Delivery Systems / Nanoparticles / Protein Corona Limits: Adult / Female / Humans / Male Language: En Year: 2016 Type: Article